title: Nanocarriers for delivery of platinum anticancer drugs.
abstract: Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clinical use especially for management of tumors of the ovary, testes, and the head and neck. However, several dose limiting toxicities associated with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life. These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy. Nanocarrier-based delivery of platinum compounds is one such area of intense research effort beginning to provide encouraging preclinical and clinical results and may allow the development of the next generation of platinum chemotherapy. This review highlights current understanding on the pharmacology and limitations of platinum compounds in clinical use, and provides a comprehensive analysis of various platinum-polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.
authors.affiliation: Department of Pharmaceutical Sciences and Center for Drug Delivery and Nanomedicine, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
authors.forename: Hardeep S
authors.initials: HS
authors.lastname: Oberoi
authors.forename: Natalia V
authors.initials: NV
authors.lastname: Nukolova
authors.forename: Alexander V
authors.initials: AV
authors.lastname: Kabanov
authors.forename: Tatiana K
authors.initials: TK
authors.lastname: Bronich
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000737:chemistry*; D055808:Drug Discovery; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015394:Molecular Structure; D053758:Nanoparticles / Q000737:chemistry*; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D017671:Platinum Compounds / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D009944:Organoplatinum Compounds; D017671:Platinum Compounds
keywords: 5-FU; 5-fluorouracil; BIC; Block ionomer complex; CDDP; CMC; CTR1; DACHPt; DMPG; DPPG; Dendrime; Drug delivery systems; HPGs; HPMA; Liposome; MWCNTs; Micelle; N-(2-hydroxypropyl)methacrylamide; NDDP; NSCLC; Nanoparticle; Nanotube; OCTs; PAMAM; PAsp; PEG; PEG-b-(polymethacrylic acid); PEG-b-PCL; PEG-b-PMAA; PEG-b-polycaprolactone; PGlu; PIC; Platinum drugs; Polymer conjugate; RES; SCLC; SPC-3; SWCNTs; block ionomer complexes; cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II); cis-dichloro(1,2-diamminocyclohexane) platinum (II); cisplatin; copper transporter 1; critical micelle concentration; dimyristoyl phosphatidylglycerol; dipalmitoyl phosphatidylglycerol; hyperbranched polyglycerols; multi-walled carbon nanotubes; non-small cell lung cancer; organic cation transporters; poly(aspartic acid); poly(glutamic acid); polyamidoamines; polyethylene glycol; polyion complex; reticuloendothelial system; single-walled carbon nanotubes; small cell lung cancer; soy phosphatidylcholine